Delivery Order SPE2DB22D3011-SPE2DB24FP8VN

Award Date 1/26/24
Potential Completion Date 1/29/24
Potential Value $2K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML. The firm-fixed-price contract has a ceiling value of $16,386.12 and a completion date of May 2, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and Amerisourcebergen, valued at up to $999,999,999.00 through...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $5,921.82 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty pharmaceutical product, in support of military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of...
The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract valued at $6,428.06 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the provision of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty pharmaceutical product, with a delivery date of April 4, 2024. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $46,649.47 firm-fixed-price delivery order is for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty medication. The contract has an ultimate completion date of October 17, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty pharmaceutical product. The delivery order has a potential value of $21,266.96 and a completion date of January 31, 2024. Amerisourcebergen Drug Corp...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $9,865.80 to Amerisourcebergen Drug Corp, a subsidiary of the for-profit organization Cencora, Inc. doing business as Amerisourcebergen. The contract is for the provision of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty pharmaceutical product. This delivery order is part of a larger, single award indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,635,723 units of the pharmaceutical product ACTEMRA 200 MG/10 ML VIAL 10ML. This $3,129.96 award has a completion date of February 13, 2024 and was issued on February 12, 2024. Amerisourcebergen Drug Corp is a for-profit organization that serves as a prime contractor for DLA, providing a wide range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a prescription medication. The $13,785.98 firm-fixed-price contract has an ultimate completion date of August 8, 2024. Amerisourcebergen holds several indefinite delivery contracts (IDCs) with the DLA and other federal agencies, valued up to $999,999,999 and $750,000, respectively, for delivering a wide...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation. The $17,387.39 fixed-price delivery order is for the pharmaceutical product ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, with a completion date of June 4, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00 through December...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a $5,261.76 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide Actemra Actpen 162 mg/0.9 ml medication with a completion date of January 26, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB24FP8VN
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML pharmaceutical products. The $1,973.16 contract has a completion date of January 29, 2024 and was awarded on January 26, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver pharmaceutical products and medical supplies to support the Department of Defense. This delivery order is not associated with any set-aside designations.

Generated 4/26/24, 11:24 AM